{"id":"NCT03552276","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.","officialTitle":"A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-07-11","primaryCompletion":"2023-09-18","completion":"2023-09-18","firstPosted":"2018-06-11","resultsPosted":"2024-11-21","lastUpdate":"2024-11-21"},"enrollment":281,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"SUNPG18_07 I (Tildrakizumab 200 mg)","otherNames":[]},{"type":"DRUG","name":"SUNPG18_07 II (Tildrakizumab 100 mg)","otherNames":[]}],"arms":[{"label":"SUNPG18_07 q4 weeks, high dose","type":"EXPERIMENTAL"},{"label":"SUNPG18_07 q12 weeks, high dose","type":"EXPERIMENTAL"},{"label":"SUNPG18_07 q12 weeks, low dose","type":"EXPERIMENTAL"},{"label":"SUNPG18_07 q4 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose","type":"EXPERIMENTAL"},{"label":"SUNPG18_07 q12 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose","type":"EXPERIMENTAL"}],"summary":"A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"upto week 208","effectByArm":[{"arm":"Tildrakizumab 200 mg q4 Weeks","deltaMin":5,"sd":null},{"arm":"Tildrakizumab 200 mg q12 Weeks","deltaMin":14,"sd":null},{"arm":"Tildrakizumab 100 mg q12 Weeks","deltaMin":36,"sd":null},{"arm":"Tildrakizumab 200 mg q4 Weeks Switched to Tildrakizumab 100 mg q12 Weeks","deltaMin":44,"sd":null},{"arm":"Tildrakizumab 200 mg q12 Weeks Switched to Tildrakizumab 100 mg q12 Weeks","deltaMin":125,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":66,"countries":["United States","Argentina","Hungary","Mexico","Poland","Russia","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":5},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Headache"]}}